Hologic’s HOLX acquisition of Biotheranostics in 2021 accelerated its entry into a large, fast-growing oncology adjacency. The business also carries higher margins than the company’s legacy service ...
First pivotal trial to use a circulating tumor DNA (ctDNA)-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer Trial showed ...
Historically, I haven't been great about managing my stress and anxiety, so whenever I come across a video or article about cortisol imbalances, my interest is piqued. Since cortisol is also called ...
Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial. Rate of medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results